Latest filing published 02 Sept 2022 for Reneo Pharmaceuticals, Inc., €26k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michael Cruse: trading record in brief
Michael Cruse, listed as senior executive, appears in our data through filings on OnKure Therapeutics, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 25 August 2021 to 1 September 2022, the count stands at 8 filings.
The open-market record is one-sided, with 7 purchases worth €65k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant. Since January 2022: 6 purchases and no sales on the market.
In size, the median ticket on the buying side is €5,871. 1 out of 7 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.
The newest entry dates from 2 September 2022: an open-market purchase of €26k, in OnKure Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Michael Cruse
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,500 shares@ US$3.39344.5% of flowCommon StockSEC:0001209191-22-048534:0Canonical exit: 30 Nov 2022 (T+90)
- 83 shares@ US$3.240.5% of flowCommon StockSEC:0001209191-22-048167:0Canonical exit: 27 Nov 2022 (T+90)
- 25,000 shares0Common StockSEC:0001209191-21-069436:0
- 2,500 shares@ US$7.446438.0% of flowCommon StockSEC:0001209191-21-053520:0Canonical exit: 23 Nov 2021 (T+90)
4 of 4 declarations
